Advances in prostate cancer treatment: Radionuclide therapy for prostate cancer.
Lutetium-177
PSMA
Prostate cancer
Radionuclide therapy
Targeted alpha therapy
Targeted beta therapy
Theranostics
Journal
Advances in cancer research
ISSN: 2162-5557
Titre abrégé: Adv Cancer Res
Pays: United States
ID NLM: 0370416
Informations de publication
Date de publication:
2024
2024
Historique:
medline:
22
9
2024
pubmed:
22
9
2024
entrez:
21
9
2024
Statut:
ppublish
Résumé
The optimal treatment of metastatic castration-resistant prostate cancer (mCRPC) continues to be challenging, given the multitude of life prolonging treatment options. Radionuclide therapy delivers concentrated doses of radiation via ionizing particles chelated to ligands or antibody-based molecules with specific tumor targets and is approved for patients with treatment resistant mCRPC. Variations of radionuclide therapies within the continuum of prostate cancer treatment are being investigated. Landmark phase III clinical trials of beta-emitting
Identifiants
pubmed: 39306369
pii: S0065-230X(24)00070-8
doi: 10.1016/bs.acr.2024.07.004
pii:
doi:
Substances chimiques
Radioisotopes
0
Radiopharmaceuticals
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
311-358Informations de copyright
Copyright © 2024. Published by Elsevier Inc.